HIV (Human Immunodeficiency Virus) Therapeutics Market by Type, Product, and Geography - Forecast and Analysis 2019-2023

The global HIV therapeutics market has the potential to grow by USD 2.44 billion during 2019-2023, and the market’s growth momentum will accelerate throughout the forecast period.

This report provides a detailed analysis of the market by geography (Asia, Europe, North America, and ROW), type (combination therapy and monotherapy), and product (reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, integrase inhibitors, and coreceptor antagonists). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors including AbbVie Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Lupin Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Market Overview

Browse TOC and LoE with selected illustrations and example pages from HIV therapeutics market report

Request a FREE sample now!

Market Competitive Analysis

The market is concentrated, and the degree of concentration will decrease during the forecast period. The vendors are focusing on technological advancements in diagnostic testing and are increasingly funding the development of novel therapies. To expand their market reach, established vendors are also focusing on adopting strategic alliances. Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., and Merck & Co. Inc. are some of the major market participants. Though the accelerating growth momentum will offer immense growth opportunities, the high cost of antiretroviral therapies will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

To help clients improve their market position, this HIV therapeutics market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market’s competitive landscape and provides information on the products offered by various companies. Moreover, this report also includes information on the upcoming HIV therapeutics market trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.

This HIV therapeutics market analysis report provides information on the production, sustainability, and prospects of several leading HIV therapeutics companies, including:

• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Johnson & Johnson Services Inc.
• Lupin Ltd., Merck & Co. Inc.
• Mylan NV
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

HIV Therapeutics Market: Segmentation by Region

For more insights on the HIV therapeutics market share of various regions Request for a FREE sample now!

There is a growing awareness about HIV and an increase in number of initiatives to end the HIV epidemic in North America. The governments are also focusing on organizing several programs and campaigns to increase awareness and funding for HIV treatment.

Over 73% of the market’s growth will originate from North America during the forecast period. The region is witnessing the increasing prevalence of newly diagnosed cases and an increase in the diagnosis of HIV. This will subsequently drive the need for novel therapeutics, fueling HIV therapeutics market growth. The US and Canada are the key markets for HIV therapeutics in this region and market growth in North America will be faster than the growth of the market in other geographies.

HIV Therapeutics Market: Segmentation by Type

Request for a FREE sample and Get more information on the market contribution of various therapeutic types

Two or more drugs from one or more drug classes are used in combination therapy for the treatment of HIV. Combination therapy has high efficiency in the treatment of HIV, and the market is witnessing the development of new combination therapies. Clinical trials on different combinations of drugs are being conducted by several vendors and researchers across the world. As the high price of combination therapy limits their preference, various government organizations are introducing reimbursement programs.

As a result, market growth in this segment will be faster than the growth of the market in the monotherapy segment. This report provides an accurate prediction of the contribution of all the segments to the growth of the HIV therapeutics market size.

HIV Therapeutics Market: Key Drivers and Trends

Various government organizations across the world have taken initiatives to end the HIV epidemic. These initiatives have created awareness across the globe about the advancements and discoveries of novel medicines for the treatment of HIV. Moreover, several organizations have also started supporting the public health response to global HIV epidemic. Initiatives such as Start Talking, Stop HIV, Stop HIV Stigma, and Let’s Stop HIV has increased the awareness about HIV and have helped in reducing the annual incidence of HIV infection in the US. With the growing awareness about HIV and the increasing number of initiatives to end the HIV epidemic will significantly support the growth of the HIV therapeutics market over the forecast period.

• There is a significant shift from traditional laboratory testing for HIV to rapid point-of-care (POC) testing.
• The preference for self-testing has been rapidly growing across developed countries.
• Mobile HIV diagnostic tools help in early detection and are critical to prevent disease progression and transmission, further requiring long-term intensive care.
• The demand for viral load diagnostics is expected to grow in the coming years.
• Similarly, there is also a growing demand for in-vitro diagnostic solutions as they enhance the detection of HIV and the progress tracking of antiretroviral treatments.
• Because of the advancements in HIV testing, the market will register a CAGR of almost 2% during 2019-2023.

Request for a FREE sample now!

HIV Therapeutics Market: Key Highlights of the Report for the Forecast Period 2019-2023

• CAGR of the market during the forecast period 2019-2023
• Detailed information on factors that will accelerate the growth of the HIV therapeutics market during the next five years
• Precise estimation of the global HIV therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the HIV therapeutics industry across Asia, Europe, North America, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of HIV therapeutics vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch